Bimonthly fluorouracil in elderly patients with metastatic colorectal cancer: a report of 50 patients.

被引:13
|
作者
Mabro, M [1 ]
Gilles-Amar, V [1 ]
Louvet, C [1 ]
Carola, E [1 ]
Maindrault-Goebel, F [1 ]
de Gramont, A [1 ]
Krulik, M [1 ]
机构
[1] Hop St Antoine, Serv Med Interne Oncol, F-75012 Paris, France
来源
REVUE DE MEDECINE INTERNE | 1999年 / 20卷 / 10期
关键词
chemotherapy; colorectal cancer; elderly; 5; fluorouracil; leucovorin;
D O I
10.1016/S0248-8663(00)80091-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose, - Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy. In order to define the contribution of chemotherapy in elderly patients, we studied the tolerance and the efficacy of first-line chemotherapy in patients with metastatic colorectal cancer. Methods. - Patients aged oiler 75 years received, as outpatient therapy, a bimonthly 48 h leucovorin and fluorouracil regimen. Evaluation was assessed every six cycles (i.e., three months). Results, - Fifty patients were studied: 28 males and 22 females, aged between 75 to 87 years, 37 with colon cancer and 13 with rectal cancer. Among 45 patients capable of being evaluated, the response rate was 44%, with six complete responses (13%) and 14 partial responses (31%). Eighteen patients had stable disease (40%) and seven patients progressive disease (16%). Median progression;free survival was 8.8 months and median survival 16.4 months. Grade 3 to 4 toxicity occurred in 20% of the patients. Performance status improved in 56% of the patients. Conclusion, - The bimonthly regimen is well tolerated in elderly patients and appears to prolong survival as well in younger patients. (C) 1999 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:863 / 868
页数:6
相关论文
共 50 条
  • [41] Comparative Effectiveness of Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer
    Satram-Hoang S.
    Lee L.
    Yu S.
    Guduru S.R.
    Gunuganti A.R.
    Reyes C.
    McKenna E.
    Journal of Gastrointestinal Cancer, 2013, 44 (1) : 79 - 88
  • [42] The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity
    Wildes, Tanya M.
    Kallogjeri, Dorina
    Powers, Brian
    Vlahiotis, Anna
    Mutch, Matthew
    Spitznagel, Edward L., Jr.
    Tan, Benjamin
    Piccirillo, Jay F.
    JOURNAL OF GERIATRIC ONCOLOGY, 2010, 1 (02) : 48 - 56
  • [43] Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
    Di Bartolomeo, Maria
    Pietrantonio, Filippo
    Martinetti, Antonia
    Buzzoni, Roberto
    Gevorgyan, Arpine
    Bajetta, Emilio
    DRUGS & AGING, 2011, 28 (02) : 83 - 91
  • [44] Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer
    Lee, JH
    Lee, JH
    Kim, TW
    Lee, KH
    Kang, YK
    Lee, JS
    Kim, SH
    Kim, HC
    Yu, CS
    Kim, JC
    Kim, WK
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2001, 16 (01) : 69 - 74
  • [45] Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
    Ocvirk, Janja
    Moltara, Maja Ebert
    Mesti, Tanja
    Boc, Marko
    Rebersek, Martina
    Volk, Neva
    Benedik, Jernej
    Hlebanja, Zvezdana
    RADIOLOGY AND ONCOLOGY, 2016, 50 (02) : 226 - 231
  • [46] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    Abdelwahab, S.
    Azmy, A.
    Abdel-aziz, H.
    Salim, H.
    Mahmoud, A.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (09) : 1487 - 1492
  • [47] First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
    Koehne, Claus-Henning
    Hofheinz, Ralf
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Fernebro, Eva
    Gamelin, Erick
    DeCosta, Lucy
    Karthaus, Meinolf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (01) : 65 - 72
  • [48] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Taniguchi, Hiroya
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1123 - 1129
  • [49] Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer
    Okamoto, Kazuaki
    Nozawa, Hiroaki
    Emoto, Shigenobu
    Murono, Koji
    Sasaki, Kazuhito
    Ishihara, Soichiro
    ONCOLOGY, 2022, 100 (11) : 576 - 582
  • [50] Oral status in patients receiving 5-fluorouracil for colorectal cancer
    Djuric, M.
    Cakic, S.
    Hadzi-Mihailovic, M.
    Petrovic, D.
    Jankovic, L.
    JOURNAL OF BUON, 2010, 15 (03): : 475 - 479